Home » Healthcare » Netherland Human Insulin Market

Netherland Human Insulin Market

Netherlands Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Netherland Human Insulin Market Size 2023	USD 196.23 million
Netherland Human Insulin Market, CGR	3.24%
Netherland Human Insulin Market Size 2032	USD 261.51 million

Market Overview

Netherland Human Insulin market size was valued at USD 196.23 million in 2023 and is anticipated to reach USD 261.51 million by 2032, at a CAGR of 3.24% during the forecast period (2023-2032).

The Netherlands Human Insulin market is driven by the rising prevalence of diabetes, growing awareness about early diagnosis and treatment, and the increasing adoption of insulin therapies among both type 1 and type 2 diabetic patients. Favorable government initiatives, improved healthcare infrastructure, and reimbursement policies further support market expansion. Technological advancements in insulin delivery systems, such as smart pens and continuous glucose monitors, are enhancing patient compliance and outcomes, thereby fueling demand. Additionally, a growing elderly population and lifestyle-related risk factors are contributing to the consistent rise in insulin usage. Key market players are investing in research and development to introduce more efficient and patient-friendly insulin formulations, which is expected to shape future growth. The trend toward personalized medicine and digital health integration is also influencing the insulin therapy landscape, offering new avenues for market development in the coming years. These factors collectively support a steady market growth trajectory.

The geographical analysis of the Netherlands Human Insulin market reveals a strong concentration of demand in urbanized regions with advanced healthcare infrastructure, such as the western and southern parts of the country. These areas benefit from better access to specialized diabetes care, greater health awareness, and wider adoption of innovative insulin delivery technologies. Rural and northern regions, while having lower population densities, are gradually enhancing their diabetes care capabilities through telemedicine and regional health programs. Key players in the Dutch human insulin market include prominent global pharmaceutical companies such as Novo Nordisk, Eli Lilly and Company, Sanofi, and Pfizer, which are recognized for their extensive insulin product portfolios and consistent R&D investments. Emerging firms like Biocon and Wockhardt are also gaining traction by offering cost-effective biosimilar options. These companies play a critical role in shaping the competitive landscape by introducing innovative therapies and improving accessibility across diverse patient demographics throughout the Netherlands.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The Netherlands Human Insulin market was valued at USD 196.23 million in 2023 and is projected to reach USD 261.51 million by 2032, growing at a CAGR of 3.24% from 2023 to 2032.

The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.

The rising prevalence of diabetes and increasing awareness about insulin therapies are key drivers for market growth.
Technological advancements in insulin delivery systems, including smart pens and continuous glucose monitoring, are shaping market trends.
The demand for personalized insulin treatments and digital health integration is driving innovation in insulin therapies.
Competitive players include Novo Nordisk, Eli Lilly, Sanofi, and emerging biosimilar manufacturers like Biocon and Wockhardt.
Market restraints include the high cost of advanced insulin devices and regulatory hurdles in introducing new products.
The market is dominated by Western and Southern Netherlands, where access to advanced healthcare and treatment options is more widespread.

Report Scope

This report segments the Netherland Human Insulin Market as follows:

Market Drivers

Rising Prevalence of Diabetes and an Aging Population

One of the primary drivers of the human insulin market in the Netherlands is the increasing prevalence of diabetes, particularly type 2 diabetes, which is closely linked to aging and lifestyle factors. The country is witnessing a demographic shift toward an older population, with a significant portion above the age of 60. This segment is at a higher risk for developing chronic conditions such as diabetes, leading to a sustained rise in insulin demand. For instance, national health data from the Dutch government highlights that diabetes-related healthcare expenditures have steadily increased, reflecting both improved diagnosis rates and lifestyle-related factors like obesity, sedentary habits, and poor diet. This growing patient base directly influences the market for human insulin, as insulin remains a cornerstone in diabetes management.

Supportive Government Policies and Healthcare Reimbursement

Government support plays a crucial role in the growth of the human insulin market in the Netherlands. The Dutch healthcare system is known for its accessibility, comprehensive coverage, and strong reimbursement policies, which include diabetes medications and insulin therapies. Government initiatives promoting early diagnosis and effective disease management contribute to a steady demand for insulin. For instance, Dutch health authorities have implemented policies ensuring that all types of insulin, as well as devices for blood glucose monitoring and insulin administration, are available with varying levels of reimbursement. Additionally, awareness campaigns and public health programs focusing on diabetes prevention and management encourage timely treatment and adherence to insulin regimens. The availability of reimbursed insulin products lowers out-of-pocket expenses for patients, thereby expanding access and increasing market penetration. This favorable regulatory and policy environment significantly contributes to sustained market growth.

Advancements in Insulin Delivery Technologies

The Netherlands has a robust healthcare infrastructure that supports the rapid adoption of innovative medical technologies, including advanced insulin delivery systems. Recent years have seen increased utilization of smart insulin pens, wearable insulin pumps, and continuous glucose monitoring (CGM) devices that integrate with insulin therapy. These technologies not only improve the precision and efficiency of insulin administration but also enhance patient compliance and quality of life. As a result, patients and healthcare providers in the Netherlands are showing a growing preference for these user-friendly and efficient delivery methods. The integration of digital health tools with insulin delivery devices also aligns with the country’s emphasis on preventive care and chronic disease management, further driving market growth.

Focus on Research, Innovation, and Personalized Medicine

The Netherlands has a strong focus on medical research and innovation, particularly in biotechnology and pharmaceutical development. Leading pharmaceutical companies and research institutions in the country are actively involved in developing next-generation insulin formulations with enhanced pharmacokinetics and better patient tolerability. Personalized medicine is gaining momentum, with a shift toward tailoring insulin therapy based on individual patient profiles, genetics, and metabolic responses. This trend is encouraging the development and adoption of more effective insulin therapies that offer improved glycemic control with fewer side effects. Furthermore, collaborative efforts between the public and private sectors continue to foster innovation, positioning the Netherlands as a key player in the advancement of human insulin therapies in the European market.

Market Trends

Technological Advancements in Insulin Delivery Systems

The Netherlands is witnessing significant advancements in insulin delivery technologies, notably the adoption of smart insulin pens, continuous glucose monitors (CGMs), and insulin pumps. These innovations offer real-time glucose monitoring and precise insulin dosing, enhancing patient compliance and glycemic control. For instance, a consensus report from the European Association for the Study of Diabetes and the American Diabetes Association highlights the increasing integration of automated insulin delivery systems into clinical care. The integration of digital health tools with insulin delivery devices aligns with the country’s emphasis on preventive care and chronic disease management, further driving market growth. Major players like Dexcom and Roche have introduced advanced CGM systems, such as Dexcom ONE+ and Accu-Chek Guide, catering to the growing demand for user-friendly and efficient diabetes management solutions.

Rising Demand for Remote Monitoring and Telehealth Solutions

The increasing prevalence of diabetes and the need for continuous monitoring have propelled the demand for remote monitoring solutions in the Netherlands. The COVID-19 pandemic accelerated the adoption of telehealth services, enabling patients to manage their condition effectively from home. For instance, Dutch healthcare reports indicate a steady increase in digital care adoption since 2013, with significant growth in home monitoring solutions. Remote monitoring technologies, including CGMs and mobile health applications, allow for real-time data tracking and timely interventions by healthcare providers, improving overall patient outcomes. This shift towards virtual care models is expected to sustain, given the benefits of convenience, cost-effectiveness, and enhanced patient engagement.

Government Initiatives and Supportive Healthcare Policies

The Dutch government has implemented various initiatives to combat diabetes and promote better disease management. Programs focusing on early detection, public health campaigns, and education aim to raise awareness about diabetes risk factors and encourage healthy lifestyle choices. Additionally, the healthcare system provides reimbursement for insulin pens and other diabetes management devices, reducing the financial burden on patients and increasing accessibility. These supportive policies play a crucial role in enhancing the adoption of insulin therapies and improving patient outcomes.

Shift Towards Personalized Medicine and Innovative Therapies

There is a growing emphasis on personalized medicine in the Netherlands, with healthcare providers tailoring insulin therapies based on individual patient profiles, genetics, and metabolic responses. This approach aims to optimize treatment efficacy and minimize adverse effects. Furthermore, research and development efforts are focused on introducing next-generation insulin formulations with improved pharmacokinetics and patient tolerability. The trend towards personalized care is expected to drive innovation in insulin therapies and contribute to the market’s growth trajectory.

Market Challenges Analysis

High Cost of Advanced Insulin Therapies and Delivery Devices

Despite the significant progress in insulin delivery technology and treatment efficacy, the high cost of advanced insulin formulations and modern delivery systems poses a considerable challenge in the Netherlands. Devices such as continuous glucose monitors (CGMs), insulin pumps, and smart insulin pens, while offering improved patient outcomes, come with substantial costs that may not be fully covered under standard insurance plans. Although the Dutch healthcare system provides broad reimbursement coverage, gaps still exist—especially for the latest or premium devices—potentially limiting access for some patient groups. Additionally, the price sensitivity among patients, combined with healthcare budget constraints, could slow the widespread adoption of these innovations. This financial barrier may lead patients and healthcare providers to opt for traditional, lower-cost alternatives, thereby impeding market growth for newer, more effective insulin solutions.

Regulatory Hurdles and Complex Reimbursement Procedures

Another critical challenge facing the Netherlands Human Insulin market is the evolving regulatory landscape and complex reimbursement mechanisms. Introducing new insulin formulations or delivery devices into the market requires navigating strict European Union and national-level regulatory frameworks, which often involves lengthy approval timelines and significant resource investments. For instance, the Dutch pricing and reimbursement system is complex and lacks a well-defined set of rules, often requiring consensus-based decision-making among governmental bodies and market participants. Moreover, the reimbursement approval process for newer insulin therapies can be time-consuming and intricate, requiring comprehensive health economic evaluations and real-world effectiveness data. These procedural complexities may reduce market agility and limit the timely availability of the most advanced treatment options for patients. In a competitive and fast-evolving therapeutic area like diabetes care, these regulatory and reimbursement challenges can significantly impact innovation, investment decisions, and overall market competitiveness.

Market Opportunities

The Netherlands Human Insulin market presents considerable opportunities driven by the country’s strong healthcare infrastructure, growing focus on digital health integration, and increasing investments in medical innovation. As the prevalence of diabetes continues to rise, there is a parallel demand for more effective, patient-friendly insulin therapies. This opens avenues for pharmaceutical companies to introduce next-generation insulin products with enhanced pharmacokinetic properties, reduced side effects, and improved patient adherence. Additionally, the Netherlands’ commitment to eHealth and digital transformation offers a fertile ground for integrating smart insulin delivery systems with mobile health applications and data-driven platforms. These tools not only support personalized treatment plans but also facilitate better disease monitoring and real-time intervention, presenting significant growth potential for tech-driven insulin solutions.

Furthermore, the supportive policy environment and active government engagement in public health initiatives provide a strong foundation for market expansion. The Netherlands encourages early diagnosis, preventive care, and chronic disease management, all of which contribute to sustained demand for insulin therapies. Collaborations between healthcare providers, research institutions, and biotech firms are fostering innovation in diabetes care, positioning the Netherlands as a hub for clinical trials and pilot programs. There is also a growing market segment among the aging population, which typically requires long-term insulin support, creating a stable and expanding customer base. In addition, the rise of biosimilar insulin products is expected to increase affordability and accessibility, making insulin therapy more widely available while promoting competitive pricing. These developments collectively present a promising landscape for stakeholders aiming to expand or enter the Dutch human insulin market.

Market Segmentation Analysis:

By Device:

The Netherlands Human Insulin market, when segmented by device type, is primarily dominated by insulin pens, which hold the largest market share due to their convenience, precision, and patient-friendly design. Pens are widely preferred by both healthcare providers and patients because they simplify dosing and reduce the discomfort typically associated with traditional administration methods. Their ease of use makes them particularly suitable for elderly patients and individuals with limited dexterity. Syringes, while still used in some cases, are witnessing a gradual decline in favor of more advanced delivery methods. However, they remain a cost-effective solution, especially for those managing higher insulin doses. The “Others” category, which includes insulin pumps and emerging digital delivery systems, is showing notable growth. This growth is driven by increased awareness and the adoption of technology-driven diabetes management tools, particularly among younger and tech-savvy patient groups. As innovation continues to advance in this space, the market is likely to see an accelerated shift towards smart and connected insulin delivery devices.

By Indication:

Segmenting the market based on indication, Type 1 Diabetes accounts for a significant share of insulin consumption, as patients with this condition are entirely dependent on lifelong insulin therapy. The early onset and chronic nature of the disease necessitate consistent and regulated insulin administration, making it a key driver for market demand. Type 2 Diabetes, while often initially managed through lifestyle changes and oral medications, increasingly requires insulin intervention in later stages, thereby contributing to a growing share of the market. The expanding aging population and lifestyle-related risk factors are further fueling insulin demand in this segment. Gestational Diabetes, though representing a smaller segment, is receiving increased attention due to its implications for both maternal and fetal health. As screening protocols improve and awareness rises, insulin therapy for gestational diabetes is becoming more commonly prescribed during pregnancy. Each indication segment plays a vital role in sustaining demand and shaping product development strategies in the Dutch insulin market.

Segments:

Based on Device:

Pens
Syringes
Others

Based on Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Based on Insulin:

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

Based on Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Based on the Geography:

Western Netherlands
Southern Netherlands
Northern Netherlands
Eastern Netherlands

Regional Analysis

Western Netherlands

The Western Netherlands holds the largest share of the human insulin market, accounting for approximately 38% of the national market. This region includes key urban and economically significant areas such as Amsterdam, The Hague, and Rotterdam, which have dense populations and advanced healthcare infrastructure. High diabetes prevalence, well-established hospitals, and access to specialized endocrinology services contribute to the dominant market position. Furthermore, a higher concentration of private clinics and research institutions facilitates faster adoption of advanced insulin delivery systems, such as smart pens and insulin pumps. Public health awareness is notably high in this region, and healthcare initiatives focused on diabetes management are actively promoted through both government and private channels. As a result, Western Netherlands continues to drive demand and innovation in the human insulin market.

Southern Netherlands

The Southern Netherlands represents the second-largest regional market, with an estimated 27% share. Cities like Eindhoven, Maastricht, and Tilburg are known for their strong healthcare systems and active public health campaigns targeting lifestyle-related diseases. The region has a well-distributed elderly population, which contributes significantly to insulin demand, especially for type 2 diabetes management. Southern Netherlands also benefits from close collaboration between local healthcare providers and pharmaceutical companies, supporting clinical trials and the introduction of innovative treatment approaches. There is increasing utilization of digital health platforms in this region, promoting personalized care and adherence to insulin therapy. While not as densely populated as the western region, Southern Netherlands compensates with a high rate of chronic disease incidence and well-funded health programs.

Northern Netherlands

The Northern Netherlands accounts for approximately 18% of the market share. This region, characterized by smaller cities and rural populations, has a comparatively lower population density but continues to show steady demand for human insulin due to rising diabetes prevalence. Although access to specialized diabetes care is more limited compared to urban centers, regional hospitals and local clinics are playing an active role in insulin distribution and patient education. Government initiatives aimed at reducing health disparities in rural areas are gradually improving diabetes management outcomes. There is also an increased focus on telemedicine and mobile health applications in the north, helping bridge the healthcare access gap and supporting remote insulin monitoring and administration.

Eastern Netherlands

The Eastern Netherlands comprises around 17% of the national human insulin market. This region includes cities such as Arnhem, Nijmegen, and Enschede, where healthcare infrastructure is relatively robust and continues to expand. While population density is moderate, the region has a well-organized network of healthcare facilities that offer comprehensive diabetes care, including insulin therapy. Eastern Netherlands has seen growing adoption of biosimilar insulin products, driven by cost-conscious health systems and patient affordability concerns. Furthermore, public-private partnerships in medical research are supporting innovation in insulin formulation and delivery. As the region continues to modernize its healthcare services and raise awareness of diabetes prevention and management, its share in the national insulin market is expected to grow gradually.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co
Eli Lilly and Company
Ypsomed

Competitive Analysis

The competitive landscape of the Netherlands Human Insulin market is dominated by several global and regional players, each focusing on innovation, market access, and expanding their product portfolios. Leading companies such as Novo Nordisk, Eli Lilly and Company, Sanofi, Pfizer, MannKind Corporation, Wockhardt, Biocon, Lupin, Tonghua Dongbao Pharmaceutical Co, and Ypsomed are key contributors to market growth. Leading companies in the market are investing heavily in research and development to introduce advanced insulin formulations with better efficacy and fewer side effects. These innovations include rapid-acting insulins, long-acting insulins, and insulin combinations that cater to the growing demand for personalized treatment plans. Biosimilars have emerged as a significant competitive force in the market, offering lower-cost alternatives to branded insulin products. The rise of biosimilars has introduced greater competition, particularly in the price-sensitive segments of the market. Moreover, the increasing integration of technology in insulin delivery, such as smart insulin pens, insulin pumps, and continuous glucose monitoring systems, is reshaping the competitive dynamics. Companies that can combine affordable treatment options with cutting-edge technology and better patient outcomes are likely to gain a competitive edge. In addition to technological advancements, market players are focusing on expanding their reach through strategic partnerships, acquisitions, and collaborations with healthcare providers. This ensures broader access to diabetes care, particularly in rural and underserved regions, helping to enhance market penetration and overall growth. The competitive environment is, therefore, driven by a mix of innovation, cost efficiency, and strategic partnerships.

Recent Developments

In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.

Market Concentration & Characteristics

The Netherlands Human Insulin market exhibits moderate concentration, dominated by a few large, global pharmaceutical companies with extensive market presence and well-established insulin product portfolios. These key players maintain significant control over the market through strong distribution networks, brand recognition, and continuous innovation in insulin therapies. While a few dominant players lead the market, the rise of biosimilars and newer entrants has increased competition, introducing a broader range of affordable insulin options. The market characteristics are defined by ongoing technological advancements, such as the integration of smart delivery devices and continuous glucose monitoring systems, which are gaining traction among healthcare providers and patients alike. Additionally, there is a growing focus on personalized medicine, with tailored insulin therapies designed to suit individual patient needs. The market also shows a trend toward increased access and affordability, driven by supportive healthcare policies and a shift toward cost-effective insulin alternatives in both public and private healthcare sectors.

Report Coverage

The research report offers an in-depth analysis based on Device, Indication, Insulin, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The Netherlands Human Insulin market is projected to grow steadily, driven by increasing diabetes prevalence and a growing demand for advanced insulin therapies.
Technological advancements, including the development of ultra-long-acting insulins like insulin icodec, are expected to enhance treatment options and patient compliance.
The rise of biosimilars is anticipated to improve accessibility and affordability, expanding patient access to insulin therapies.
Integration of artificial intelligence in insulin therapy is poised to personalize treatment plans, optimizing glucose control and patient outcomes.
Government initiatives promoting early diabetes detection and management are likely to increase the adoption of insulin therapies.
Aging demographics and lifestyle factors are contributing to a higher incidence of type 2 diabetes, increasing the demand for insulin products.
Homecare and telehealth solutions are gaining popularity, facilitating remote monitoring and management of insulin therapy.
Collaborations between pharmaceutical companies and technology firms are expected to drive innovation in insulin delivery systems.
Educational programs aimed at improving diabetes management are likely to enhance patient adherence to insulin regimens.
Competitive pricing strategies and improved reimbursement policies are anticipated to make insulin therapies more accessible to a broader population.

CHAPTER NO. 1 : INTRODUCTION 19

1.1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.1.2. Key Benefits for Stakeholders 19

1.1.3. Target Audience 20

1.1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. Human Insulin Market Snapshot 21

2.1.1. Netherlands Human Insulin Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23

3.1. Russia-Ukraine and Israel-Palestine War Impacts 23

CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 24

4.1. Introduction 24

4.2. Market Drivers 25

4.2.1. Driving Factor 1 Analysis 25

4.2.2. Driving Factor 2 Analysis 26

4.3. Market Restraints 27

4.3.1. Restraining Factor Analysis 27

4.4. Market Opportunities 28

4.4.1. Market Opportunity Analysis 28

4.5. Porter’s Five Forces Analysis 29

4.6. Value Chain Analysis 30

4.7. Buying Criteria 31

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32

5.1. Import Analysis by Netherlands 32

5.1.1. Netherlands Human Insulin Market Import Volume/Revenue, By Netherlands, 2018 – 2023 32

5.2. Export Analysis by Netherlands 33

5.2.1. Netherlands Human Insulin Market Export Volume/Revenue, By Netherlands, 2018 – 2023 33

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34

6.1. Demand Analysis by Netherlands 34

6.1.1. Netherlands Human Insulin Market Demand Volume/Revenue, By Netherlands, 2018 – 2023 34

6.2. Supply Analysis by Netherlands 35

6.2.1. Netherlands Human Insulin Market Supply Volume/Revenue, By Netherlands, 2018 – 2023 35

CHAPTER NO. 7 : PRODUCTION ANALYSIS 36

7.1. Production Analysis by Netherlands 36

7.1.1. Netherlands Human Insulin Market Production Volume/Revenue, By Netherlands, 2018 – 2023 36

CHAPTER NO. 8 : PRICE ANALYSIS 37

8.1. Price Analysis by Type 37

8.1.1. Netherlands Human Insulin Market Price, By Type, 2018 – 2023 37

8.1.2. Netherlands Type Market Price, By Type, 2018 – 2023 37

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38

9.1. Key Raw Materials and Suppliers 38

9.2. Key Raw Materials Price Trend 38

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39

10.1. Manufacturing Cost Analysis 39

10.2. Manufacturing Process 39

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40

11.1. Company Market Share Analysis – 2023 40

11.1.1. Netherlands Human Insulin Market: Company Market Share, by Volume, 2023 40

11.1.2. Netherlands Human Insulin Market: Company Market Share, by Revenue, 2023 41

11.1.3. Netherlands Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 41

11.1.4. Netherlands Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 42

11.2. Netherlands Human Insulin Market Company Volume Market Share, 2023 43

11.3. Netherlands Human Insulin Market Company Revenue Market Share, 2023 44

11.4. Company Assessment Metrics, 2023 45

11.4.1. Stars 45

11.4.2. Emerging Leaders 45

11.4.3. Pervasive Players 45

11.4.4. Participants 45

11.5. Start-ups /SMEs Assessment Metrics, 2023 45

11.5.1. Progressive Companies 45

11.5.2. Responsive Companies 45

11.5.3. Dynamic Companies 45

11.5.4. Starting Blocks 45

11.6. Strategic Developments 46

11.6.1. Acquisitions & Mergers 46

New Product Launch 46

Netherlands Expansion 46

11.7. Key Players Product Matrix 47

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48

12.1. PESTEL 48

12.1.1. Political Factors 48

12.1.2. Economic Factors 48

12.1.3. Social Factors 48

12.1.4. Technological Factors 48

12.1.5. Environmental Factors 48

12.1.6. Legal Factors 48

12.2. Adjacent Market Analysis 48

CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY TYPE SEGMENT ANALYSIS 49

13.1. Human Insulin Market Overview, by Type Segment 49

13.1.1. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

13.1.2. Human Insulin Market Attractiveness Analysis, By Type 51

13.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 51

13.1.4. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

13.2. Pens 53

13.3. Syringes 54

13.4. Others 55

13.5. Type 4 56

13.6. Type 5 57

CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY APPLICATION SEGMENT ANALYSIS 58

14.1. Human Insulin Market Overview, by Application Segment 58

14.1.1. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

14.1.2. Human Insulin Market Attractiveness Analysis, By Application 60

14.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 60

14.1.4. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

14.2. Type 1 Diabetes 62

14.3. Type 2 Diabetes 63

14.4. Gestational Diabetes 64

14.5. Application 4 65

14.6. Application 5 66

CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY END-USER SEGMENT ANALYSIS 67

15.1. Human Insulin Market Overview, by End-user Segment 67

15.1.1. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

15.1.2. Human Insulin Market Attractiveness Analysis, By End-user 69

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69

15.1.4. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

15.2. Rapid-acting insulin 71

15.3. Short-acting insulin 72

15.4. Intermediate-acting insulin 73

15.5. Others 74

15.6. End-user 5 75

CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76

16.1. Human Insulin Market Overview, by Technology Segment 76

16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 78

16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78

16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

16.2. Technology 1 80

16.3. Technology 2 81

16.4. Technology 3 82

CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83

17.1. Human Insulin Market Overview, by Distribution Channel Segment 83

17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 85

17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85

17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

17.2. Hospital Pharmacies 87

17.3. Drug Stores and Retail Pharmacies 88

17.4. Online Providers 89

17.5. Distribution Channel 4 90

17.6. Distribution Channel 5 91

CHAPTER NO. 18 : HUMAN INSULIN MARKET – NETHERLANDS ANALYSIS 92

18.1. Type 92

18.1.1. Netherlands Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 92

18.2. Netherlands Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 92

18.3. Application 93

18.3.1. Netherlands Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 93

18.3.2. Netherlands Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 93

18.4. End-user 94

18.4.1. Netherlands Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

18.4.2. Netherlands Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 94

18.5. Technology 95

18.5.1. Netherlands Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 95

18.5.2. Netherlands Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 95

18.6. Distribution Channel 96

18.6.1. Netherlands Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96

18.6.2. Netherlands Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96

CHAPTER NO. 19 : COMPANY PROFILES 97

19.1. Novo Nordisk A/S 97

19.1.1. Company Overview 97

19.1.2. Product Portfolio 97

19.1.3. Swot Analysis 97

19.1.4. Business Strategy 98

19.1.5. Financial Overview 98

19.1.6. MannKind Corporation 99

19.1.7. Pfizer 99

19.1.8. Wockhardt 99

19.1.9. Biocon 99

19.1.10. Lupin 99

19.1.11. Tonghua Dongbao Pharmaceutical Co 99

19.1.12. Eli Lilly and Company 99

19.1.13. Ypsomed 99

19.1.14. Company 10 99

19.1.15. Company 11 99

19.1.16. Company 12 99

19.1.17. Company 13 99

19.1.18. Company 14 99

CHAPTER NO. 20 : RESEARCH METHODOLOGY 100

20.1. Research Methodology 100

20.1.1. Phase I – Secondary Research 101

20.1.2. Phase II – Data Modeling 101

Company Share Analysis Model 102

Revenue Based Modeling 102

20.1.3. Phase III – Primary Research 103

20.1.4. Research Limitations 104

Assumptions 104

List of Figures

FIG NO. 1. Netherlands Human Insulin Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for Netherlands Human Insulin Market 29

FIG NO. 3. Value Chain Analysis for Netherlands Human Insulin Market 30

FIG NO. 4. Netherlands Human Insulin Market Import Volume/Revenue, By Netherlands, 2018 – 2023 32

FIG NO. 5. Netherlands Human Insulin Market Export Volume/Revenue, By Netherlands, 2018 – 2023 33

FIG NO. 6. Netherlands Human Insulin Market Demand Volume/Revenue, By Netherlands, 2018 – 2023 34

FIG NO. 7. Netherlands Human Insulin Market Supply Volume/Revenue, By Netherlands, 2018 – 2023 35

FIG NO. 8. Netherlands Human Insulin Market Production Volume/Revenue, By Netherlands, 2018 – 2023 36

FIG NO. 9. Netherlands Human Insulin Market Price, By Type, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. Human Insulin Market – Company Volume Market Share, 2023 43

FIG NO. 18. Human Insulin Market – Company Revenue Market Share, 2023 44

FIG NO. 19. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Type 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 51

FIG NO. 22. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

FIG NO. 23. Netherlands Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. Netherlands Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. Netherlands Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. Netherlands Human Insulin Market for Type 4, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. Netherlands Human Insulin Market for Type 5, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Application 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 60

FIG NO. 31. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

FIG NO. 32. Netherlands Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. Netherlands Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. Netherlands Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. Netherlands Human Insulin Market for Application 4, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. Netherlands Human Insulin Market for Application 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. Netherlands Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. Netherlands Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. Netherlands Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. Netherlands Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. Netherlands Human Insulin Market for End-user 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. Netherlands Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. Netherlands Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. Netherlands Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. Netherlands Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. Netherlands Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. Netherlands Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. Netherlands Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. Netherlands Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

List of Tables

TABLE NO. 1. : Netherlands Human Insulin Market: Snapshot 18

TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 24

TABLE NO. 4. : Netherlands Human Insulin Market Revenue, By Type, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : Netherlands Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : Netherlands Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : Netherlands Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 90

TABLE NO. 9. : Netherlands Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 90

TABLE NO. 10. : Netherlands Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 91

TABLE NO. 11. : Netherlands Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 91

TABLE NO. 12. : Netherlands Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : Netherlands Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : Netherlands Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : Netherlands Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93

Frequently Asked Questions

What is the current size of the Netherland Human Insulin?

The Netherlands Human Insulin market size was valued at USD 196.23 million in 2023 and is projected to reach USD 261.51 million by 2032, growing at a CAGR of 3.24%.

What factors are driving the growth of the Netherland Human Insulin?

The market is driven by the rising prevalence of diabetes, aging population, technological advancements in insulin delivery, and supportive government policies.

What are some challenges faced by the Netherland Human Insulin?

Challenges include the high cost of advanced insulin therapies and complex regulatory and reimbursement procedures.

Who are the major players in the Netherland Human Insulin?

Major players include Novo Nordisk, Eli Lilly and Company, Sanofi, Pfizer, Wockhardt, Biocon, and MannKind Corporation.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –